Evaluation of the Hemodynamic Significance of Myocardial Bridge by Coronary Blood Fractional Flow Reserve

Sponsor
Peking University Third Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04958395
Collaborator
(none)
20
12

Study Details

Study Description

Brief Summary

This study clarified the influence of myocardial bridge on coronary hemodynamics by clarifying FFR and d-FFR to guide clinical intervention and treatment.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: FFR and d-FFR

Detailed Description

Myocardial bridge is a congenital anatomical abnormality, which is generally considered to be a benign change, but individual can cause angina, myocardial infarction and even sudden death. Previously, it was believed that the degree of myocardial ischemia induced by myocardial bridge was related to factors such as the location, length, and systolic stenosis of the myocardial bridge shown by coronary angiography.However, in recent years, more and more evidence has suggested that there is a high degree of mismatch between anatomical stenosis and its function.Studies have shown that FFR and d-FFR can accurately evaluate the functional significance of stenotic lesions.This study intends to enroll patients who underwent coronary angiography due to chest pain and confirmed the left anterior descending artery (LAD) simple myocardial bridge systolic stenosis ≥30%, and the pressure guide wire was used to measure the FFR and d-FFR of the myocardial bridge lesion under static and dobutamine stress.Analyze the relationship between these functional parameters and the anatomical morphological characteristics of the myocardial bridge and other possible clinical influencing factors, and explore the influence of the morphological characteristics of the myocardial bridge on myocardial hemodynamics,so as to clarify the degree of myocardial bridge shown by angiography may induce obvious myocardial ischemia, which requires clinical intensive intervention.

Study Design

Study Type:
Observational
Actual Enrollment :
20 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of the Hemodynamic Significance of Myocardial Bridge by Coronary Blood Fractional Flow Reserve
Actual Study Start Date :
Nov 1, 2014
Actual Primary Completion Date :
Oct 31, 2015
Actual Study Completion Date :
Oct 31, 2015

Arms and Interventions

Arm Intervention/Treatment
Myocardial bridge

Measure FFR and d-FFR

Diagnostic Test: FFR and d-FFR
Measure FFR and d-FFR

Outcome Measures

Primary Outcome Measures

  1. Morphological index of myocardial bridge [All indicators were completed within 1 week of coronary angiography.]

    The minimum lumen diameter of the target vessel

Secondary Outcome Measures

  1. Exercise electrocardiogram [72 hours after coronary angiography]

    ST segment depression time

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with chest pain aged ≥18 years old, regardless of gender;

  • Coronary angiography shows a solitary myocardial bridge with systolic diameter stenosis ≥30% in LAD;

  • Have the ability to complete an ECG exercise test;

  • Sign informed consent and are willing to participate in the intended study.

Exclusion Criteria:
  • Patients with acute coronary syndrome;

  • Coronary angiography shows that the diameter of atherosclerosis in the non-myocardial bridge area of LAD is ≥30%;

  • RCA or LCX has severe fixed stenosis, diameter stenosis ≥70% or FFR<0.75, and no interventional therapy is accepted;

  • Hypertrophic obstructive cardiomyopathy or more than moderate heart valve disease;

  • Atrial fibrillation or severe slow or rapid arrhythmia;

  • Heart failure with NYHA ≥ Grade III;

  • Uncontrolled hypertension or systolic blood pressure <100mmHg;

  • Asthma or severe chronic obstructive pulmonary disease;

  • Severe liver and kidney dysfunction;

  • Allergic to contrast agents.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Study Director: Liyun He, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04958395
Other Study ID Numbers:
  • 2014188
First Posted:
Jul 12, 2021
Last Update Posted:
Jul 12, 2021
Last Verified:
Nov 1, 2014
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 12, 2021